- Major market movements today were dominated by significant corporate news and currency market developments, with particular focus on the healthcare and technology sectors. The US100 led the decline, down 0.72% amid pressure in the technology sector. The US500 fell 0.26%, while the US30 slid 0.50%.
- European markets also traded mostly lower, with the W20 showing the steepest decline (-1.67%) among major European indices. The ITA40 fell 0.78%, while the UK100 managed to stay barely positive (+0.04%). The DE40 and FRA40 declined 0.45% and 0.21% respectively.
- Moderna (MRNA.US) experienced a dramatic 23% decline after substantially reducing its 2025 revenue guidance to $1.5-2.5 billion, down from the previous $2.5-3.5 billion forecast. The company announced aggressive cost-cutting measures, including $1 billion in reductions for 2025 and an additional $500 million in 2026, responding to weakening Covid vaccine demand.
- In tech sector developments, Apple (AAPL) faces mounting challenges as iPhone sales declined 5% in Q4, with global market share dropping to 18%. The company's delayed AI rollout, particularly in China, has impacted performance. Additionally, Apple confronts legal challenges in the UK regarding App Store practices and increased EU scrutiny over new developer fee structures.
- The Biden administration's new AI export controls significantly affected Nvidia (NVDA), whose shares fell 3.7%. While 18 close allies received exemptions, over 120 countries face new restrictions requiring government approval for AI model exports and overseas computing facilities.
- ECB’s Villeroy commented on the French budget puzzle, stating that France is not at risk of not being able to finance itself. He added that French GDP growth could pick up in 2026 and 2027.
- NY Fed’s 3-year expected inflation rose in December to 3% (previously: 2.6%)
- In major M&A news, Johnson & Johnson (JNJ) announced a $14.6 billion acquisition of Intra-Cellular Therapies at $132 per share, sending ITCI shares up 35% in premarket trading. The deal strengthens J&J's CNS portfolio with lumateperone and ITI-1284.
- Currency markets saw significant movement as the euro dropped below 1.02, reaching its lowest level since November 2023. The decline intensified following Friday's strong US jobs report, which forced traders to reassess Fed rate cut expectations. Goldman Sachs now forecasts the euro to fall to 0.97 in six months.
- In energy markets, new US sanctions on Russia have raised supply concerns, though Rystad Energy expects Brent crude to remain range-bound around $80 per barrel. Goldman Sachs suggests prices could test $85 per barrel amid the uncertainty.
- Precious metals faced significant pressure across the board, with silver leading the decline (-2.21%), followed by gold (-1.11%). Palladium and platinum also weakened, dropping 0.50% and 0.25% respectively. The sector's weakness comes amid dollar strength and rising Treasury yields.
- Cryptocurrencies trend lower. Bitcoin declines 2.3% to $91,540, while Ethereum slides 7.7% to $2981.
- The market now awaits Wednesday's US CPI data for further insights into the Federal Reserve's policy path, while monitoring the euro's ability to maintain support near parity levels.
GBPUSD slightly up after stronger than expected UK labour market data
Morning wrap: Wall Street gains amid hopes of renewed US–Iran talks🗽
USA Rare Earth Acquires Key Brazilian Rare Earth Metal Mines ⛏️
US OPEN: Return of geopolitical concerns hits markets 💥
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.
